검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Tarlatamab |
Overview Company | GlaxoSmithKline |
Overview Modality | ANTIBODY |
Overview Target | Extensive-Stage Small Cell Lung Cancer |
Overview Indication | Neoplasms |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
MoA Mechanism | bispecific that, combined with an EpCAM×CD3 TCE, provides tumor-dependent costimulation and enhances anti-tumor cytotoxicity mediated by the TCE |
MoA Biomarker | HER2×CD2 compensates for the loss of CD58 expression |
PK/PD Half-life | 11.2 h |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Combination therapy with a novel CD2-targeted costimulatory bispecific antibody overcomes limitations of CD3 T cell engager treatment for solid tumors.. CD3 T cell engagers (TCEs) have transformed hematologic oncology, but dose-liming toxicity and the absence of adequate costimulation have limited TCE success in solid tumors. Consequently, to date, only one classical TCE developed for solid tumors… |
Toxicology CRS | Reported |
Clinical Primary efficacy | ORR 57.1% |
Clinical ORR | 57.1% |
Clinical PFS | 6.5 |
Clinical OS | NA |
Clinical Result source | ClinicalTrials.gov NCT04885998 |
Clinical Data Tier / Score | A · 68 |
Clinical Program phase | PHASE_3 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Tarlatamab |
Overview Company | GlaxoSmithKline |
Overview Modality | ANTIBODY |
Overview Target | Extensive-Stage Small Cell Lung Cancer |
Overview Indication | Neoplasms |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
MoA Mechanism | bispecific that, combined with an EpCAM×CD3 TCE, provides tumor-dependent costimulation and enhances anti-tumor cytotoxicity mediated by the TCE |
MoA Biomarker | HER2×CD2 compensates for the loss of CD58 expression |
PK/PD Half-life | 11.2 h |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Combination therapy with a novel CD2-targeted costimulatory bispecific antibody overcomes limitations of CD3 T cell engager treatment for solid tumors.. CD3 T cell engagers (TCEs) have transformed hematologic oncology, but dose-liming toxicity and the absence of adequate costimulation have limited TCE success in solid tumors. Consequently, to date, only one classical TCE developed for solid tumors… |
Toxicology CRS | Reported |
Clinical Primary efficacy | ORR 57.1% |
Clinical ORR | 57.1% |
Clinical PFS | 6.5 |
Clinical OS | NA |
Clinical Result source | ClinicalTrials.gov NCT04885998 |
Clinical Data Tier / Score | A · 68 |
Clinical Program phase | PHASE_3 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
추천 비교
추천 비교